52mg左炔诺孕酮宫内节育系统最长8年避孕有效性与安全性:Mirena扩展试验结果
美国多中心单臂Mirena扩展试验纳入使用52mg左炔诺孕酮宫内节育系统4.5至5年的18至35岁女性,评估延长使用至8年的避孕有效性与安全性。第6至8年3年Pearl指数为0.28(95%CI 0.03-1.00),3年累积失败率0.68%(0.17-2.71),发生2例妊娠。治疗中出现不良事件249/362例(68.8%),停药率38.4%(139/362)。
要点
- 第6至8年3年Pearl指数0.28(95%CI 0.03-1.00),3年累积失败率0.68%(0.17-2.71)。
- 治疗中出现不良事件249/362例(68.8%),其中65例(18.0%)事件被认为与52mg左炔诺孕酮宫内节育系统相关。
- 停药率38.4%(139/362),最常见原因为希望妊娠(12.2%,44/362)。
核心结论
- 52mg左炔诺孕酮宫内节育系统最初获批使用5年,延长使用至8年仍保持高避孕有效性、使用者满意度和良好的安全性。
- 完成8年使用者中98.7%(220/223)对继续使用52mg左炔诺孕酮宫内节育系统保持满意。
- 31例因希望妊娠提前停药且有可评估生育恢复数据的女性中,24例报告治疗后1年内妊娠,12个月生育恢复率为77.4%。
- 上述发现支持希望继续治疗的女性将52mg左炔诺孕酮宫内节育系统使用延长至8年。
研究设计与样本
- 美国多中心单臂研究,纳入已使用52mg左炔诺孕酮宫内节育系统4.5至5年、年龄18至35岁的现有使用者。
- 评估延长使用期间52mg左炔诺孕酮宫内节育系统的避孕有效性(Pearl指数)和累积失败率(Kaplan-Meier法),并评价出血结局和不良事件。
- 第6年起始有362例参与者,243例进入第8年,223例完成8年使用;平均(标准差)年龄29.2(±2.9)岁,略微超过半数参与者有分娩史,第8年末所有参与者年龄≤36岁。
主要发现
- 第6至8年发生2例妊娠,均为装置在位;第6年妊娠部位未确定并自行消退,第7年妊娠为异位妊娠并经甲氨蝶呤治疗消退。
- 第6至8年3年Pearl指数(95%CI)为0.28(0.03-1.00),3年累积失败率为0.68%(0.17-2.71)。
- 第6年、第7年、第8年Pearl指数分别为0.34(0.01-1.88)、0.40(0.01-2.25)、0.00(0.00-1.90)。
- 第6至8年3年异位妊娠Pearl指数为0.14(0.00-0.77)。
- 治疗中出现不良事件249/362例(68.8%),65例(18.0%)事件被认为与52mg左炔诺孕酮宫内节育系统相关;停药率38.4%(139/362),最常见原因为希望妊娠(12.2%,44/362)。
临床怎么用
- 原文结论认为上述发现支持希望继续治疗的女性将52mg左炔诺孕酮宫内节育系统使用延长至8年。
局限性
- 未纳入足够数量使用52mg左炔诺孕酮宫内节育系统避孕并治疗月经过多的女性,无法评估该适应证的延长使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The 52-mg levonorgestrel-releasing intrauterine system is an established, long-acting contraceptive option with approved use for up to 7 years. OBJECTIVE: The Mirena Extension Trial evaluated the efficacy and safety of the 52-mg levonorgestrel-releasing intrauterine system during extended use beyond 5 and up to 8 years. STUDY DESIGN: This was a multicenter, single-arm study in the United States, enrolling existing users of the 52-mg levonorgestrel-releasing intrauterine system, aged 18 to 35 years, who have had the system for 4.5 to 5 years. We assessed the contraceptive efficacy (Pearl Index) and cumulative failure rate (using the Kaplan-Meier method) of the 52-mg levonorgestrel-releasing intrauterine system during extended use. We also evaluated bleeding outcomes and adverse events. RESULTS: Of the 362 participants starting year 6, 243 entered and 223 completed 8 years of 52-mg levonorgestrel-releasing intrauterine system use. Just more than half the participants were parous. The mean (standard deviation) age was 29.2 (±2.9) years, and all participants were aged ≤36 years at the end of year 8. Two pregnancies occurred, both with the device in situ. The year 6 pregnancy was of undetermined location and resolved spontaneously. The pregnancy in year 7 was ectopic and resolved with methotrexate treatment. In both cases, the 52-mg levonorgestrel-releasing intrauterine system was removed and the participants left the trial. For years 6 to 8, the 3-year Pearl Index (95% confidence interval) was 0.28 (0.03-1.00) with a 3-year cumulative failure rate of 0.68% (0.17-2.71). Pearl Indexes for years 6, 7, and 8 were 0.34 (0.01-1.88), 0.40 (0.01-2.25), and 0.00 (0.00-1.90), respectively. The 3-year (years 6-8) ectopic pregnancy Pearl Index was 0.14 (0.00-0.77). We found treatment-emergent adverse events in 249 of 362 participants (68.8%), with 65 (18.0%) events considered to be related to the 52-mg levonorgestrel-releasing intrauterine system. The discontinuation rate was 38.4% (139/362), most commonly because of desire for pregnancy (12.2%, 44/362). During extended use beyond 5 years and up to 8 years, participants reported a decrease in the mean number of bleeding or spotting days with approximately half of the women experiencing amenorrhea or infrequent bleeding. We did not enroll a sufficient number of women using the 52-mg levonorgestrel-releasing intrauterine system for contraception and heavy menstrual bleeding to assess extended use for that indication. At the end of year 8, most (98.7%, 220/223) of the participants who completed the study remained satisfied with the continued use of the 52-mg levonorgestrel-releasing intrauterine system. Of the 31 women who discontinued early because of desire for pregnancy with evaluable data for return-to-fertility analysis, 24 reported a posttreatment pregnancy within 1 year, giving a 12-month return-to-fertility rate of 77.4%. CONCLUSION: The 52-mg levonorgestrel-releasing intrauterine system, initially approved for 5 years, maintains high contraceptive efficacy, user satisfaction, and a favorable safety profile through 8 years of use. Participants reported 26 posttreatment pregnancies in total, of which 24 occurred in women who had discontinued the 52-mg levonorgestrel-releasing intrauterine system because of a desire for pregnancy. Of note, among women who elected to continue use through 8 years, bleeding patterns remained highly favorable. These findings support continued 52-mg levonorgestrel-releasing intrauterine system use for up to 8 years in women who wish to continue treatment.
引用
- Jensen JT, Lukkari-Lax E, Schulze A, et al. Contraceptive efficacy and safety of the 52-mg levonorgestrel intrauterine system for up to 8 years: findings from the Mirena Extension Trial. Am J Obstet Gynecol. 2022. PMID: 36096186. doi:10.1016/j.ajog.2022.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。